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Objective: To elucidate the benefits of using probiotics in the prevention of necrotizing 
enterocolitis (NEC) and its complications in preterm newborns.
Method: This was a systematic review of randomized controlled trials, which included 
studies retrieved from three databases (MEDLINE, Embase, and LILACS), using a 
combination of the terms (necrotizing enterocolitis) AND (probiotics). 
Results: 11 randomized trials were included, totaling 2,887 patients, 1,431 in the 
probiotic group and 1,456 in the control group. There was a reduction in the incidence of 
NEC (NNT = 25), overall death (NNT = 34), and neonatal sepsis (NNT = 34) in the probiotic 
group compared to the control group. Patients that received probiotic supplementation 
had lower food reintroduction time (p < 0.001) and hospitalization time (p < 0.001) 
when compared to those not receiving probiotics. There was no difference in mortality 
caused by NEC.
Conclusion: In premature newborns, the use of probiotics is effective as a prophylaxis 
for NEC and its complications.
© 2013 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda.  
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Introduction
Necrotizing enterocolitis (NEC) is multifactorial disease that 
results from the interaction between the loss of integrity of 
the intestinal mucosa and the host response to this damage. 
It is determined by intestinal ischemia, mucosal damage, 
edema, ulceration, and passage of air or bacteria through 
the wall, resulting in necrosis of the mucosa and intestinal 
wall.
The main preexisting factors that cause increased risk 
for developing NEC are prematurity, enteral feeding, 
and colonization by pathogenic microorganisms such as 
Escherichia coli, Klebsiella, Clostridium perfringens, 
Staphylococcus epidermidis and Rotavirus.1
This is the most prevalent emergency of the 
gastrointestinal tract in the neonatal period.2 Its incidence 
is highly variable, affecting 2% to 22% of newborns with very 
low birth weight (< 1,500 g).2,3
The occurrence of NEC is inversely related to gestational 
age at birth, due to the physiological intestinal immaturity 
of preterm neonates. Therefore, probiotics, a group of 
organisms capable of improving this clinical picture, have 
been studied in order to fight disease progression.
Probiotics were first described in the literature by 
Lilly and Stillwell in 1965, as growth-promoting factors 
produced by certain microorganisms. Recently, they have 
been described as living organisms which, when included in 
the diet in adequate amounts, can bring health benefits to 
the host.4 As microorganisms able to colonize the digestive 
tract by adhering to the intestinal epithelium, producing 
antimicrobial substances, and modulating the immune 
response and host metabolism, probiotics have been 
discussed regarding their usefulness for preterm infants.5,6 
This study aimed to elucidate the benefits of probiotics 
in the prevention of NEC and its complications in preterm 
infants. 
Methods
Study identification and selection
In order to perform a systematic analysis of the available 
evidence on the efficacy of probiotics in the prevention of 
NEC, a literature search strategy was used, which included 
searches carried out in MEDLINE, Embase, and LILACS. The 
searches were completed in May 2012. 
The MEDLINE search was performed through PubMed 
(www.ncbi.nlm.nih.gov/pubmed) and was adapted by using 
the terms (necrotizing enterocolitis) AND (probiotics). 
The same strategy was used in the Embase database. For 
LILACS, the terms (enterocolite) AND (probióticos) were 
used.
Also, a manual search was conducted through the 
references of pre-selected studies and published reviews 
on the subject.
Inclusion and exclusion criteria
Study design: only randomized and controlled trials (phase 
III studies) were included.
Patients: premature newborns (< 34 weeks of gestational 
age) and/or very low birth weight (< 1,500 g at birth) 
regardless of gestational age. Studies that included patients 
with more than 34 weeks of gestational age and 1,500 g at 
birth and those in which it was not possible to establish 
these limits were excluded from the analysis. 
Intervention: Newborns who received supplementation with 
probiotics (regardless of the nature, mode of preparation, 
and dose) added to enteral nutrition with human milk and/
or formula;
Control: Newborns who received only enteral nutrition with 






Eficácia dos probióticos na profilaxia de enterocolite necrosante em recém-nascidos 
prematuros: revisão sistemática e meta-análise
Resumo 
Objetivo: Elucidar os benefícios do uso de probióticos na prevenção de enterocolite 
necrosante (ECN) e de suas complicações em recém-nascidos prematuros. 
Método: Revisão sistemática de ensaios clínicos randomizados, que incluiu pesquisas 
efetuadas em três bases de dados (MEDLINE, EMBASE e LILACS), utilizando a combinação 
dos termos (necrotizing enterocolitis) AND (probiotics). 
Resultados: Foram incluídos 11 ensaios clínicos randomizados, totalizando 2.887 pacien-
tes, sendo 1.431 no grupo Probiótico e 1.456 no grupo Controle. Houve redução na 
incidência de ECN (NNT = 25), de morte global (NNT = 34) e sepse neonatal (NNT = 34) 
no grupo Probiótico em relação ao grupo Controle. Pacientes alimentados com suple-
mentação de probióticos tiveram tempo de reintrodução alimentar (p < 0,001) e de 
hospitalização (p < 0,001) menor quando comparados aos que não receberam. Não houve 
diferença na mortalidade causada por ECN. 
Conclusão: Em recém-nascidos prematuros, o uso de probióticos é eficaz na profilaxia 
de ECN e de suas complicações.
© 2013 Sociedade Brasileira de Pediatria. Publicado por Elsevier Editora Ltda.  
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Analyzed outcomes
The outcomes analyzed were incidence of NEC ≥ Bell 
stage II,7 overall mortality, mortality from NEC, sepsis 
incidence, time to reintroduction of oral feeding, and 
hospitalization.
Methodological quality and internal validity
A detailed assessment of quality of the studies was 
conducted, aiming to evaluate the strength of evidence 
and the validity of their inclusion in this review. The Jadad 
scale8 was used, and only studies with a score equal to or 
greater than 3 were included in this review. 
The individual characteristics of each study 
included in the review were analyzed according to the 
Consolidated Standards of Reporting Trials (CONSORT) 
recommendations.9
Statistical analysis
All data were analyzed by intention to treat, thus the 
study participants were assessed in groups to which they 
were randomized regardless of treatment and protocol 
irregularities. The possible losses to follow-up were 
considered unfavorable clinical outcome.
The measures of effectiveness or damage expressed 
in absolute numbers were analyzed by the difference in 
absolute risk, adopting a confidence interval of 95%. For 
all statistically significant results, the numbers needed 
to treat (NNT) and numbers needed to harm (NNH) were 
calculated.
For the analysis of continuous data, the differences of 
weighted means between the groups were used. The studies 
that did not express data as means and their respective 
standard deviations were not included in the analyses. 
Heterogeneity and sensitivity analysis
Inconsistencies between trials were estimated using the 
chi-squared test for heterogeneity, and quantified using the 
I2 test. A value above 50% was considered significant. 
A sensitivity analysis was performed, including only 
studies that obtained results with power > 80%. 
Results
Study selection
268 studies were retrieved through electronic searches 
(MEDLINE = 190; Embase = 73, and LILACS = 5). Of these, 18 
randomized and controlled trials were selected to be read in 
full.10-27 Six studies were identified through manual search, 
as they did not fit the strategy used28,29 or were indexed in 
another database.30-33 After this phase, eight studies were 
excluded because they did not meet inclusion criteria: five 
studies did not evaluate the study population;10,14,19,25,29 
one study did not assess the selected outcomes;18 and two 
studies were classified as Jadad < 3.13,28 Four studies were 
not included because they were published in the Chinese 
language, which made data comprehension and extraction 
impossible.30-33 
Thus, this review included data from twelve randomized 
and controlled trials,11,12,15-17,20-24,26,27 totaling 2,907 patients, 
with 1,441 in the probiotics group and 1,466 in the control 
group.
Primary study description
Data on the interventions evaluated in each primary study 
are described in Table 1.
Effect of probiotics on necrotizing enterocolitis
In the probiotics group, the incidence of NEC stage ≥ 2 was 
3.2%, whereas in the control group it was 7.2%. There was a 
decrease in the absolute risk by 4.0% (95% CI: 0.02 to 0.06, 
p < 0.001, I2 = 37%; Figure 1) and it was necessary to treat 
25 patients to obtain this benefit.
Effect of probiotics on mortality
The mortality rate in the study group was 5.5%, whereas 
in the control group it was 8.4%. Probiotics reduce the 
absolute risk of death by 3.0% (95% CI: 0.01 to 0.05, p < 
0.002; I2 = 59%; Figure 1) and it was necessary to treat 34 
patients to obtain this benefit. 
When excluding the study that generated high 
heterogeneity,12 the effect achieved in the previous analysis 
is sustained (p < 0.002 and I2 = 14%).
Only five primary studies analyzed mortality from 
NEC.12,15,20,24,27 There was no statistical difference between 
the probiotic and placebo groups (2.6% vs. 3.0%, p = 0.64, 
I2 = 0%; Figure 1). 
Effect of probiotics on sepsis
All studies analyzed the incidence of neonatal sepsis as 
the outcome. Patients receiving probiotics had a lower 
incidence of sepsis when compared to those not receiving 
them, but with no significant difference (17.9% vs. 20.6%, 
95% CI: 0.00 to 0.05, p = 0.05, I2 = 57%; Figure 1).
The same effect is obtained when excluding the study that 
generated significant heterogeneity21 (p = 0.32, I2 = 21%). 
Effect of probiotics on time to oral feeding 
reintroduction
Eight primary studies evaluated the time to oral feeding 
reintroduction.15,17,20,21,23,24,26,27 The patients that received 
supplementation with probiotics had oral feeding 
reintroduction, on average, three days earlier than the 
control group (95% CI: 2.78 to 3.69 days, p <0.001). 
However, this result is related to a high heterogeneity 
(I2 = 94%).
Effect of probiotics on time of hospitalization
Six primary studies assessed the duration of hospitalization 
in a neonatal intensive care unit.11,16,20,22,23,27 Two studies 
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provided data as medians and were not included in the 
meta-analysis.11,27 Patients who received probiotics stayed, 
on average, six days less in the hospital (95% CI: 5.12 to 
7.09 days, p < 0.001, I2 = 88%) when compared to those 
who did not.
Power of primary studies
The power established in each primary study, regarding 
each outcome, is described in Table 2.
Analysis of sensitivity
Through the analysis of sensitivity, including only studies 
that had statistical power greater than 80%, patients 
who received probiotics had a lower incidence of NEC 
(NNT = 13). There was no difference in overall mortality, 
mortality from NEC, and the incidence of sepsis between 
the groups.
Discussion
Although NEC is still a major challenge in neonatology, 
much information has been obtained to elucidate its 
pathogenesis, allowing a better study of its management 
and prevention. Special attention has been given to 
supplementation with probiotics for preterm infants, 
especially those with very low birth weight, in an attempt 
to reduce the incidence of this disease. 
Probiotics are living microorganisms offered as nutritional 
supplements that act in the intestine of the host organism 
by regulating the local bacterial flora. They act by 
improving gastrointestinal permeability and increasing the 
resistance of the mucosa against bacterial penetration. 
Regarding the protection mechanisms, they: (i) increase 
the resistance of the intestinal barrier against the passage 
of bacteria and their toxins, (ii) modify the host response 
in relation to microbial products, (iii) increase the mucosal 
response to IgA, (iv) produce bactericidal substances, and 
(v) competitively exclude potential pathogens.5,6 
This review aimed to assess the best evidence available 
in the literature to elucidate the benefits of probiotics in 
preterm neonates. Only randomized and controlled trials 
with well-defined protocols were included, to control 
possible biases as much as possible. The validity of the 
results can be potentially compromised due to different 
doses and preparation methods of the intervention being 
studied. Non-inclusion of the four studies published in the 
Chinese language, for which it was not possible to perform 
critical analysis, must also be considered. 
The set of results showed, with consistent data, that 
enteral administration of probiotics reduced the incidence 
of severe cases of NEC, mortality, and sepsis, as well as 
Table 1 Data on interventions evaluated in primary studies.
Study Probiotic agent Dose and duration Milk
Millar et al.11 Lactob GG 108 CFU twice a day, for 14 days Human and/or formula
Dani et al.12 Lactob GG 6x109 CFU once a day until discharge Human and/or formula
Bin-Nun et al.15 Bifidobac infantis 3.5x108 CFU of each, once a day up to corrected gest.  Human and/or formula 
  age of 36 weeks
 Bifidobac bifidum 
 Strepto thermophilus
Lin et al.16 Lactob acidophilus 106 organisms of each, twice a day from seventh day Human 
  until discharge
 Bifidobac infantis
Manzoni et al.17 Lactob casei 6x109 CFU once a day, from third day until six weeks Human 
  or until discharge
Lin et al.20 Lactob acidophilus 2x109 CFU once a day up to six weeks Human and formula
 Bifidobac bifidum
Manzoni et al.21 Lactob rhamnosus 6x109 CFU once day, for four to six weeks Human and/or formula 
  or until disacharge
Rouge et al.22 Bifidobac longum 108 CFU once a day until discharge Human and/or formula
 Lactob rhamnosus
Samanta et al.23 Bifidobac infantis 2.5x109 CFU once a day until discharge Human
 Bifidobac bifidum 
 Bifidobac longum 
 Lactob acidophilus
Mihatsch et al.24 Bifidobac lactis 1.2x1010 CFU/kg once a day, until six weeks Human and/or formula
Braga et al.26 Bifidobac breve 3.5x107 to 3.5x109 CFU once a day, from second Human 
  to 30th day or until discharge
 Lactob casei
Sari et al.7 Lactob sporogenes 3.5x108 CFU once a day, until discharge Human and/or formula
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 Probiotics  Control  Risk Difference Risk Difference
Study Events Total Events Total Weight F-M, fixed, 95% CI F-M, fixed, 95% CI
Incidence of ECN
Bin-Nun et al.15 1 72 10 73 5.0% −0.12 [−0.21, −0.04]
Braga et al.26 0 122 4 121 8.4% −0.03 [−0.07, 0.00]
Dani et al.12 4 295 8 290 20.3% −0.01 [−0.04, 0.01]
Lin et al.16 2 180 10 187 12.7% −0.04 [−0.08, −0.01]
Lin et al.20 9 222 18 221 15.4% −0.04 [−0.09, 0.00]
Manzoni et al.17 1 39 3 41 2.8% −0.05 [−0.14, 0.05]
Manzoni et al.21 0 151 10 168 11.0% −0.06 [−0.10, −0.02]
Mihatsch et al.24 4 93 5 90 6.3% −0.01 [−0.08, 0.05]
Rouge et al.22 2 45 1 49 3.3% 0.02 [−0.05, 0.10]
Samanta et al.23 5 91 15 95 6.4% −0.10 [−0.19, −0.02]
Sari et al.27 17 121 20 121 8.4% −0.02 [−0.12, 0.07]
Subtotal (95% CI)  1431  1456 100.0% −0.04 [−0.06, −0.02]
Total of envents 45  104
Heterogeneity: Chi2 = 15.85, df = 10 (p = 0.10); I2 = 37%
Overall effect test: Z = 4.97 (p < 0.00001)
Overall mortality
Bin-Nun et al.15 3 72 8 73 5.0% −0.07 [−0.15, 0.02]
Braga et al.26 26 122 27 121 8.4% −0.01 [−0.11, 0.09]
Dani et al.12 0 295 2 290 20.3% −0.01 [−0.02, 0.00]
Lin et al.16 7 180 20 187 12.7% −0.07 [−0.12, −0.02]
Lin et al.20 7 222 13 221 15.4% −0.03 [−0.07, 0.01]
Manzoni et al.17 5 39 6 41 2.8% −0.02 [−0.17, 0.01]
Manzoni et al.21 6 151 12 168 11.0% −0.03 [−0.08, 0.02]
Mihatsch et al.24 4 93 2 90 6.3% 0.02 [−0.03, 0.07]
Rouge et al.22 2 45 4 49 3.3% −0.04 [−0.13, 0.06]
Samanta et al.23 4 91 14 95 6.4% −0.10 [−0.19- −0.02]
Sari et al.27 14 121 14 121 8.4% 0.00 [−0.08, 0.08]
Subtotal (95% CI)  1431  1456 100.0% −0.03 [−0.05, −0.01]
Total of events 78  122
Heterogeneity: Chi2 = 24.38, df = 10 (p = 0.007); I2 = 59%
Overall effect test: Z = 3.17 (p = 0.002)
Mortality due to ECN
Bin-Nun et al.15 0 72 3 73 9.1% −0.04 [−0.09, 0.01]
Dani et al.12 0 295 2 290 36.6% −0.01 [−0.02, 0.00]
Lin et al.20 7 222 7 221 27.7% −0.00 [−0.03, 0.03]
Mihatsch et al.24 3 93 1 90 11.4% 0.02 [−0.02, 0.06]
Sari et al.27 11 121 11 121 15.1% 0.00 [−0.07, 0.07]
Subtotal (95% CI)  803  795 100.0% −0.00 [−0.02, 0.01]
Total of events 21  24
Heterogeneity: Chi2 = 3.66, df = 4 (p = 0.45); I2 = 0%
Heterogeneity: Chi2 = 15.85, df = 10 (p = 0.10); I2 = 37%
Overall effect test: Z = 4.97 (p < 0.00001)
Incidence of sepse
Bin-Nun et al.15 31 72 24 73 5.0% −0.10 [−0.06, −0.26]
Braga et al.26 40 122 42 121 8.4% −0.02 [−0.14, 0.10]
Dani et al.12 14 295 12 290 20.1% −0.01 [−0.03, 0.04]
Lin et al.16 22 180 36 187 12.6% −0.07 [−0.14, −0.00]
Lin et al.20 25  222 28 221 15.2% −0.01 [−0.07, 0.05]
Manzoni et al.17 19 39 22 41 2.8% −0.05 [−0.27, 0.17]
Manzoni et al.21 7 151 29 168 10.9% −0.13 [−0.19, −0.06]
Mihatsch et al.24 30 93 30 90 6.3% −0.01 [−0.15, 0.13]
Millar MR.11 0 10 0 10 0.7% −0.00 [−0.17, 0.17]
Rouge et al.22 15 45 13 49 3.2% 0.07 [−0.12, 0.25]
Samanta et al.23 13 91 28 95 6.4% −0.15 [−0.27, −0.04]
Sari et al.27 40 121 36 121 8.3% −0.03 [−0.08, 0.15]
Subtotal (95% CI)  1441  1466 100.0% −0.03 [−0.05, −0.00]
Total of envents 256  104
Heterogeneity: Chi2 = 23.10, df = 11 (p = 0.02); I2 = 52%
Overall effect test: Z = 1.96 (p < 0.05)
Figure 1 Meta-analysis analyzing the efficacy of probiotics in preterm neonates. 95% CI, 95% confidence interval; df, degrees 
of freedom; ECN, necrotizing enterocolitis; F, female; I², heterogeneity test; M, male.
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presenting a shorter time until oral feeding reintroduction 
and shorter hospitalization stay. Although the numbers 
needed to treat in relation to NEC prophylaxis (NNT = 25) 
and mortality (NNT = 34) are relatively high, these can be 
counterbalanced by the high incidence of premature births, 
especially in countries with socioeconomic and cultural 
problems, and also by the easy handling and low costs 
related to probiotics. Considering the extremely fragile 
patients, susceptible to infections, complications and 
comorbidities, it is believed that these supplements, when 
available, deserve more attention. 
Based on the available data, it can be inferred that 
probiotics are another useful tool in pediatric clinical 
practice. However, further studies are needed to assess the 
best preparation methods and doses, as well as the types of 
probiotics to be used. 
Some reviews on the subject have been published in 
recent years, and similarly to the present study, showed the 
benefits of probiotic supplementation.34-36 Small differences 
regarding methodological issues are found among these 
publications; for instance, regarding the search strategy 
and databases used, gestational age (27-37 weeks), and 
weight of the newborn. Nonetheless, there was a decrease 
in the incidence of NEC in all analyses. Wang et al.,36 in 
the last review published on the subject, were the first 
to attempt to stratify the data regarding the species of 
probiotics. Both Lactobacillus and Bifidobacteria were 
found to be effective. 
Some authors consider the available evidence as 
sufficient for the adoption of this type of therapy into 
routine practice, and claim that new studies on the subject 
are unnecessary and also unethical. Others are more 
cautious and claim that the studies have methodological 
flaws, that the safety of probiotics in relation to the 
invasion of microorganisms in the intestinal mucosa is not 
fully established, and that the methods of preparation are 
very heterogeneous.37
Four clinical trials registered with ClinicalTrials.gov 
including approximately 1,500 patients are under progress; 
in the future, they must be included in a data update, and 
may thus elucidate the benefits obtained so far.
Moreover, it should be clarified that only two selected 
studies had sufficient power to confirm the results. 
Conclusion
The synthesis of evidence shows that supplementation 
with probiotics reduces the incidence of severe NEC in 
premature infants. 
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